ATE532533T1 - Von antikörpern abgeleitete vektoren für den transfer von substanzen in zellen - Google Patents

Von antikörpern abgeleitete vektoren für den transfer von substanzen in zellen

Info

Publication number
ATE532533T1
ATE532533T1 AT98941540T AT98941540T ATE532533T1 AT E532533 T1 ATE532533 T1 AT E532533T1 AT 98941540 T AT98941540 T AT 98941540T AT 98941540 T AT98941540 T AT 98941540T AT E532533 T1 ATE532533 T1 AT E532533T1
Authority
AT
Austria
Prior art keywords
cells
antibodies
substances
transfer
derived vectors
Prior art date
Application number
AT98941540T
Other languages
English (en)
Inventor
Therese Ternynck
Alexandre Avrameas
Gerard Buttin
Stratis Avrameas
Marie-Francoise Saron
Bruno Blondel
Therese Couderc
Susan Michelson
Donato Zipeto
Original Assignee
Pasteur Institut
Univ Paris Curie
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pasteur Institut, Univ Paris Curie filed Critical Pasteur Institut
Application granted granted Critical
Publication of ATE532533T1 publication Critical patent/ATE532533T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C07K16/112—Retroviridae (F), e.g. leukemia viruses
    • C07K16/114—Lentivirus (G), e.g. human immunodeficiency virus [HIV], feline immunodeficiency virus [FIV] or simian immunodeficiency virus [SIV]
    • C07K16/1147—Regulatory proteins, e.g. trans-activator of transcription [TAT], rev or vacuolar protein targeting [VPT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6883—Polymer-drug antibody conjugates, e.g. mitomycin-dextran-Ab; DNA-polylysine-antibody complex or conjugate used for therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/44—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/80—Immunoglobulins specific features remaining in the (producing) cell, i.e. intracellular antibodies or intrabodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/32011—Picornaviridae
    • C12N2770/32611—Poliovirus
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Virology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Biotechnology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AT98941540T 1997-08-04 1998-08-04 Von antikörpern abgeleitete vektoren für den transfer von substanzen in zellen ATE532533T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9709972A FR2766826B1 (fr) 1997-08-04 1997-08-04 Vecteurs derives d'anticorps pour le transfert de substances dans les cellules
PCT/FR1998/001740 WO1999007414A1 (fr) 1997-08-04 1998-08-04 Vecteurs derives d'anticorps pour le transfert de substances dans les cellules

Publications (1)

Publication Number Publication Date
ATE532533T1 true ATE532533T1 (de) 2011-11-15

Family

ID=9510010

Family Applications (1)

Application Number Title Priority Date Filing Date
AT98941540T ATE532533T1 (de) 1997-08-04 1998-08-04 Von antikörpern abgeleitete vektoren für den transfer von substanzen in zellen

Country Status (8)

Country Link
US (3) US6635248B1 (de)
EP (1) EP1001815B1 (de)
JP (2) JP4365022B2 (de)
AT (1) ATE532533T1 (de)
AU (1) AU8988098A (de)
CA (1) CA2298934C (de)
FR (1) FR2766826B1 (de)
WO (1) WO1999007414A1 (de)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1052288A1 (de) * 1999-05-10 2000-11-15 Transgene S.A. Komplex zur Ubertragung einer anionischen Substanz in einen Zell
EP1052287A3 (de) * 1999-05-10 2003-07-09 Transgene S.A. Komplex zur Übertragung von einem interessierenden anionischen Substanz auf einer Zelle
WO2001057072A2 (en) * 2000-02-07 2001-08-09 Wisconsin Alumni Research Foundation Pharmacologically active antiviral peptides and methods of their use
US8003595B2 (en) 2000-03-01 2011-08-23 Cellectis Amino acid sequences facilitating penetration of a substance of interest into cells and/or cell nuclei
FR2805821B1 (fr) 2000-03-01 2004-01-16 Diatos Sequences d'acides amines facilitant la penetration d'une substance d'interet a l'interieur des cellules et/ou des noyaux cellulaires
US7033597B2 (en) 2000-10-13 2006-04-25 Université de Lausanne Intracellular delivery of biological effectors
US6960648B2 (en) 2000-10-13 2005-11-01 Universite De Lausanne Intracellular delivery of biological effectors
US7049286B2 (en) 2001-08-30 2006-05-23 Diatos, S.A. Insulin conjugates and methods of use thereof
WO2003080115A1 (fr) * 2002-03-22 2003-10-02 Bipha Corporation Complexes peptide hydrophile - immunoglobuline
EP1512696A1 (de) * 2003-08-14 2005-03-09 Diatos Aminsäuresequenz, die den Transfer von Substanzen von Interesse in das Innere von Zellen und/oder Zellkernen erleichtern
ES2330115T3 (es) 2003-08-14 2009-12-04 Cellectis Composicion antibacteriana, mas particilarmente contra las bacterias gram-negativas, que comprende un peptido y un agente antibacteriano ventajosamente hidrofobo.
US7265092B2 (en) 2004-09-30 2007-09-04 Kai Pharmaceuticals, Inc. Pharmaceutical formulation
WO2006122787A1 (en) 2005-05-18 2006-11-23 Ablynx Nv Serum albumin binding proteins
EP1797901A1 (de) 2005-12-16 2007-06-20 Diatos Zelldurchlässige Peptidkonjugate zum Transfer von Nukleinsäuren in Zellen
EP1818395A1 (de) 2006-02-08 2007-08-15 Diatos Zusammensetzungen und Verfahren zur Behandlung der Lysosomen-Speichererkrankungen
KR101394768B1 (ko) * 2006-03-30 2014-05-21 드라이스 파마슈티컬스 아이엔씨 캄토테신-세포 투과 펩티드 결합체 및 이를 포함하는 약학 조성물
WO2008074839A2 (en) 2006-12-19 2008-06-26 Ablynx N.V. Amino acid sequences directed against gpcrs and polypeptides comprising the same for the treatment of gpcr-related diseases and disorders
EP2102244A2 (de) 2006-12-19 2009-09-23 Ablynx N.V. Gegen metalloproteinase aus der adam-familie gerichtete aminosäuresequenzen und diese enthaltende polypeptide zur behandlung von mit adam in zusammenhang stehenden krankheiten und störungen
CA2676340A1 (en) * 2007-01-19 2008-07-24 Kai Pharmaceuticals, Inc. Methods of use of epsilon inhibitor compounds for the attenuation of pain
AU2009235467A1 (en) 2008-04-07 2009-10-15 Ablynx Nv Single variable domains against the Notch pathways
WO2010014915A2 (en) * 2008-07-31 2010-02-04 Molecular Transfer, Inc. Novel peptides for use in transfection
NZ595461A (en) 2009-04-10 2013-01-25 Ablynx Nv Improved amino acid sequences directed against il-6r and polypeptides comprising the same for the treatment of il-6r related diseases and disorders
ES2643034T3 (es) 2009-06-05 2017-11-21 Ablynx N.V. Construcciones de Nanobody contra el virus respiratorio sincicial humano (VRSH) trivalentes para la prevención y/o el tratamiento de infecciones de las vías respiratorias
WO2011064382A1 (en) 2009-11-30 2011-06-03 Ablynx N.V. Improved amino acid sequences directed against human respiratory syncytial virus (hrsv) and polypeptides comprising the same for the prevention and/or treatment of respiratory tract infections
JP5986931B2 (ja) 2011-02-02 2016-09-06 公益財団法人微生物化学研究会 血液脳関門を透過する薬物輸送体、ペプチド及びその用途
CA2827170A1 (en) 2011-02-11 2012-08-16 David M. Hilbert Monovalent and multivalent multispecific complexes and uses thereof
WO2014087010A1 (en) 2012-12-07 2014-06-12 Ablynx N.V. IMPROVED POLYPEPTIDES DIRECTED AGAINST IgE

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5166320A (en) * 1987-04-22 1992-11-24 University Of Connecticut Carrier system and method for the introduction of genes into mammalian cells
US5597573A (en) * 1989-05-04 1997-01-28 Igen, Inc. Lipid-A analogs: new monosaccharide and disaccharide intermediates for eliciting therapeutic antibodies and for antitumor and antiviral activities
US5296348A (en) * 1989-05-16 1994-03-22 The Wistar Institute Of Anatomy And Biology Methods for screening monoclonal antibodies for therapeutic use
US5521291A (en) * 1991-09-30 1996-05-28 Boehringer Ingelheim International, Gmbh Conjugates for introducing nucleic acid into higher eucaryotic cells
US5622929A (en) * 1992-01-23 1997-04-22 Bristol-Myers Squibb Company Thioether conjugates
AU675929B2 (en) * 1992-02-06 1997-02-27 Curis, Inc. Biosynthetic binding protein for cancer marker
US5861156A (en) * 1993-01-08 1999-01-19 Creative Biomolecules Methods of delivering agents to target cells
DE4412629A1 (de) * 1993-04-14 1995-01-26 Boehringer Mannheim Gmbh Nukleinsäure-transferpeptide und deren Verwendung zur Einschleusung von Nukleinsäuren in eukaryontische Zellen
US5851829A (en) * 1993-07-16 1998-12-22 Dana-Farber Cancer Institute Method of intracellular binding of target molecules
US5733782A (en) 1993-10-25 1998-03-31 Creative Biomolecules, Inc. Methods and compositions for high protein production from non-native DNA
FR2736642B1 (fr) * 1995-07-10 1997-09-12 Pasteur Institut Immunovecteurs, notamment anticorps et fragments d'anticorps utilisables pour le transport intracellulaire et intranucleaire de principes biologiquement actifs notamment d'haptenes, de proteines et d'acides nucleiques
WO1997032602A1 (en) * 1996-03-08 1997-09-12 The Regents Of The University Of California DELIVERY SYSTEM USING mAb 3E10 AND MUTANTS AND/OR FUNCTIONAL FRAGMENTS THEREOF

Also Published As

Publication number Publication date
FR2766826B1 (fr) 2001-05-18
US20070098741A1 (en) 2007-05-03
JP2009159988A (ja) 2009-07-23
JP4365022B2 (ja) 2009-11-18
WO1999007414A1 (fr) 1999-02-18
EP1001815B1 (de) 2011-11-09
US20030206900A1 (en) 2003-11-06
AU8988098A (en) 1999-03-01
US6635248B1 (en) 2003-10-21
EP1001815A1 (de) 2000-05-24
CA2298934C (fr) 2011-04-26
JP2001513335A (ja) 2001-09-04
US7628987B2 (en) 2009-12-08
FR2766826A1 (fr) 1999-02-05
CA2298934A1 (fr) 1999-02-18
JP4482054B2 (ja) 2010-06-16

Similar Documents

Publication Publication Date Title
ATE532533T1 (de) Von antikörpern abgeleitete vektoren für den transfer von substanzen in zellen
AR243234A1 (es) Un gen quimerico modificado que codifica una proteina insecticida de bacillus thuringiensis,un vector que lo contiene, y un metodo para mejorar la expresion de un gen heterologo.
NO20002360D0 (no) Kjemiske forbindelser
DE69805806D1 (de) Gettermaterialien zur spaltung von ammoniak
DE69938867D1 (de) Verfahren und verwendung von anordungen von proteinfixierungsmitteln
TR200101484T2 (tr) Alzheimer hastalığı sekretazı
BR0009206A (pt) Isolamento e análise de proteina
BR9810586A (pt) Peptìdio de aglutinação de integrin cìclico, composição farmacêutica que compreende o mesmo, processos para inibição e ensaio de aglutinação para identificar agentes de aglutinação de integrin
ID23172A (id) Metode yang diperbaiki untuk pengolahan protein c teraktivasi
CA2413156A1 (en) Expression vectors
DK0914331T3 (da) Neuroaktive peptider
EP0585257A4 (de) Für natürliche killerzellen spezifische dna- und aminosäuresequenz.
DE69828045D1 (de) Verbindungen, ihre herstellung und ihre verwendung für den transfer von nucleinsäuren in zellen
ATE368688T1 (de) Peptide, deren herstellung und verwendung zur bindung von immunglobulinen
DE69822057D1 (de) Hochkonsistentes Elastomer zur Handhabung von Flüssigkeiten
DE69802389D1 (de) Verbindungen verwendbar als effektoren von neuroexcitatorischen aminosäure-empfindlichen rezeptoren des zentralnervensystems, ihre herstellung and ihre biologischen verwendungen
NO995182D0 (no) Pattedyrcytokinlignende faktor 7
DE69738256D1 (de) Nachstummedium für den auswählenden nachweis von staphylokokkus
DE69800720D1 (de) Reagenz zur Färbung von Blutzellen
DK1082423T3 (da) Cyclin E2-gener og -proteiner
DE59911457D1 (de) Behälter zur aufnahme eines betriebsmittels für den betrieb von brennstoffzellen
GB9816514D0 (en) Novel method
DE69829240D1 (de) Für temperaturstabiles Diaphorase Kodierendes Gen
DE69821296D1 (de) Mischen von flüssigen Gasen
HU9800782D0 (en) Novel antibody, renin-active substance containing the same and prorenin assay reagent using the same